Obesity Gene Therapy Program (Entos Pharmaceuticals)

N/A

Report date: 2026/04/10 20:01:49

Base Information

Drug NameObesity Gene Therapy Program (Entos Pharmaceuticals)

Drug Alias NameGLP-1/GiP/Amylin Mono or Combination Therapy (Entos Pharmaceuticals)

ClassificationCell and gene therapy > Gene therapy

Mechanisms of ActionAmylin receptor modulatorsGlucose-Dependent Insulinotropic Polypeptide Receptor modulatorsGlucagon-like peptide 1 receptor modulators

TargetsAmylin ReceptorGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor

Therapy Area/IndicationsObesityMetabolic Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEntos Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesEntos Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsObesityMetabolic Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A